Fisher Asset Management Boosts Eli Lilly Stake

Institutional investor increases holding in pharmaceutical giant by 3.5%

Mar. 2, 2026 at 4:47pm

Got story updates? Submit your updates here. ›

Fisher Asset Management LLC, a major institutional investor, has increased its stake in Eli Lilly and Company by 3.5%, adding 150,595 shares to its portfolio. The firm now owns 4,453,062 shares of the pharmaceutical company, representing approximately 0.47% of Eli Lilly's total outstanding shares.

Why it matters

This move by Fisher Asset Management, a respected investment management firm, signals continued confidence in Eli Lilly's long-term growth potential. As a major shareholder, Fisher's increased stake could indicate the firm's belief in Eli Lilly's pipeline of new drugs and therapies, as well as the company's ability to maintain its market leadership position.

The details

According to the company's most recent SEC filing, Fisher Asset Management purchased an additional 150,595 shares of Eli Lilly in the third quarter, bringing its total holding to 4,453,062 shares. This represents a 3.5% increase in the firm's position and makes Eli Lilly the 21st largest holding in Fisher's portfolio, valued at approximately $3.4 billion.

  • Fisher Asset Management disclosed the increased stake in Eli Lilly in a filing with the SEC on March 2, 2026.

The players

Fisher Asset Management LLC

A major institutional investment firm that manages over $1 trillion in assets for clients worldwide.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients globally.

Got photos? Submit your photos here. ›

The takeaway

Fisher Asset Management's increased stake in Eli Lilly underscores the firm's confidence in the pharmaceutical company's long-term growth prospects. As a major shareholder, Fisher's investment decision could signal positive sentiment among institutional investors towards Eli Lilly's pipeline and market positioning.